Bausch Health Companies Inc.

NYSE:BHC Rapporto sulle azioni

Cap. di mercato: US$2.1b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bausch Health Companies Gestione

Gestione criteri di controllo 2/4

Bausch Health Companies' Il CEO è Tom Appio, nominato in May2022, e ha un mandato di 2.25 anni. la retribuzione annua totale è $ 15.88M, composta da 7.4% di stipendio e 92.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.11% delle azioni della società, per un valore di $ 2.42M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 8.1 anni.

Informazioni chiave

Tom Appio

Amministratore delegato

US$15.9m

Compenso totale

Percentuale dello stipendio del CEO7.4%
Mandato del CEO2.3yrs
Proprietà del CEO0.1%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione8.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06
Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24
Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Dec 30

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Dec 22

Bausch Health: Things To Consider Before Investing

Dec 11

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic

Sep 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tom Appio rispetto agli utili di Bausch Health Companies?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$471m

Mar 31 2024n/an/a

-US$455m

Dec 31 2023US$16mUS$1m

-US$592m

Sep 30 2023n/an/a

-US$963m

Jun 30 2023n/an/a

-US$186m

Mar 31 2023n/an/a

-US$357m

Dec 31 2022US$13mUS$1m

-US$225m

Sep 30 2022n/an/a

US$254m

Jun 30 2022n/an/a

US$43m

Mar 31 2022n/an/a

-US$407m

Dec 31 2021US$10mUS$854k

-US$948m

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$4mUS$775k

-US$560m

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$2b

Mar 31 2020n/an/a

-US$2b

Dec 31 2019US$4mUS$769k

-US$2b

Sep 30 2019n/an/a

-US$616m

Jun 30 2019n/an/a

-US$917m

Mar 31 2019n/an/a

-US$2b

Dec 31 2018US$4mUS$730k

-US$4b

Sep 30 2018n/an/a

-US$3b

Jun 30 2018n/an/a

-US$2b

Mar 31 2018n/an/a

-US$805m

Dec 31 2017US$3mUS$650k

US$2b

Compensazione vs Mercato: La retribuzione totale di Tom ($USD 15.88M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Tom è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Tom Appio (62 yo)

2.3yrs

Mandato

US$15,878,578

Compensazione

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Thomas Appio
CEO & Director2.3yrsUS$15.88m0.11%
$ 2.5m
John Barresi
Senior VP2.2yrsUS$1.40m0.0055%
$ 118.1k
Seana Carson
Executive VP & General Counsel2.3yrsUS$3.16m0.023%
$ 482.6k
Jean-Jacques Charhon
Chief Financial Officerno dataNessun datoNessun dato
Mirza Dautbegovic
Executive VP & COO2.6yrsNessun dato0.024%
$ 520.5k
Kathleen Fitzpatrick
Executive VP and Chief HR & Communications Officer2.6yrsNessun datoNessun dato
Josh Coyle
Senior Vice President of Sales & Salix1.6yrsNessun datoNessun dato
Tage Ramakrishna
Chief Medical Officer and President of R&Dno dataNessun datoNessun dato
Jeff Hartness
Executive VP of Market Access4.2yrsNessun datoNessun dato
Graham Jackson
Senior VP & Chief Quality Officer2.6yrsNessun datoNessun dato
Cees Heiman
Senior Vice President of Europe & Canada2.6yrsNessun datoNessun dato
Donald Pearl
Senior Vice President of Ortho Dermatologicsno dataNessun datoNessun dato

2.4yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di BHC è considerato esperto (durata media dell'incarico 2.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Thomas Appio
CEO & Director2.3yrsUS$15.88m0.11%
$ 2.5m
John Paulson
Independent Chairman2.2yrsUS$812.50k0.000060%
$ 1.3k
Robert Power
Independent Director16yrsUS$389.55k0.0018%
$ 38.5k
H. Fibiger
Chairman of External Advisory Boardno dataUS$2.00mNessun dato
Sarah Kavanagh
Independent Director8.1yrsUS$718.28k0%
$ 0
Robert Lenox
Member of the External Advisory Board15.4yrsNessun datoNessun dato
Kathleen Clarence-Smith
Member of the External Advisory Board15.4yrsNessun datoNessun dato
Karoly Nikolich
Member of the External Advisory Board15.4yrsNessun datoNessun dato
Brett Icahn
Independent Director3.4yrsUS$691.72k0.00020%
$ 4.3k
Amy Wechsler
Independent Director8.2yrsUS$377.50k0.011%
$ 245.7k
Steven Miller
Independent Director3.4yrsUS$381.31k0.031%
$ 658.1k
Christian Garcia
Independent Directorless than a yearNessun datoNessun dato

8.1yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BHC sono considerati esperti (durata media dell'incarico 8.1 anni).